舘 佳彦

Medicine & Life Sciences

1. Hepacivirus 100%
2. Chronic Hepatitis C 87%
3. glecaprevir and pibrentasvir 66%
4. Genotype 51%
5. Hepatocellular Carcinoma 50%
6. Japan 47%
7. Multicenter Studies 46%
8. Fibrosis 44%
9. Antiviral Agents 42%
10. Interferons 38%
11. Sustained Virologic Response 37%
12. Elasticity Imaging Techniques 34%
13. Liver 34%
14. Liver Cirrhosis 33%
15. velpatasvir 30%
16. Sofosbuvir 24%
17. Therapeutics 20%
18. asunaprevir 19%
19. Prospective Studies 19%
20. BMS-790052 18%
21. 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide 16%
22. Virus Diseases 16%
23. Safety 16%
24. Biopsy 16%
25. Liver Diseases 15%
26. Acoustics 14%
27. peginterferon alfa-2b 13%
28. Fetal Proteins 13%
29. Skeletal Muscle 13%
30. Chronic Disease 13%
31. Abdominal Pain 11%
32. Bilirubin 11%
33. Amino Acid Substitution 11%
34. Pruritus 11%
35. Elderly 11%
36. Ribavirin 11%
37. Radiation 11%
38. Mutation 10%
39. Hepatitis C 10%
40. Fatty Liver 10%
41. Confidence Intervals 9%
42. Interleukins 9%
43. Lithotripsy 9%
44. Cholecystitis 8%
45. Hepatitis B virus 8%
46. Gallbladder 8%
47. Hepatitis B Surface Antigens 8%
48. Odds Ratio 8%
49. Chronic Renal Insufficiency 8%
50. Albumins 7%